Understanding how EBV affects lymphoma in patients with weakened immune systems
Official title: EBV-Positive Diffuse Large B-cell Lymphoma: Defining Biologic Determinants of Disease Pathogenesis in Immunodeficiency
Funded at University of Vermont & St Agric College · NIH-11222775 · Data updated 2026-11-12
This study is looking at how the Epstein-Barr virus affects a type of cancer called diffuse large B-cell lymphoma, especially in people with weakened immune systems, like those with HIV, to help find better ways to diagnose and treat this illness.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Vermont & St Agric College NIH-funded |
| Lab location | 1 site (Burlington, United States) |
| Project start | November 1, 2024 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $160,084 |
| NIH project number | 5P20GM125498-07 |
| Project ID | NIH-11222775 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with diffuse large B-cell lymphoma who are also immunocompromised, particularly those with HIV.
✕Less likely to help
Patients with DLBCL who are not immunocompromised or do not have EBV involvement may not benefit from this research.
What this research studies
This research investigates the role of Epstein-Barr virus (EBV) in diffuse large B-cell lymphoma (DLBCL), particularly in patients with weakened immune systems due to conditions like HIV. The study aims to identify the biological characteristics of EBV(+) DLBCL and how these relate to patient outcomes in different regions, including sub-Saharan Africa and the United States. By analyzing genomic data and clinical variables, the researchers hope to improve diagnostic methods and uncover new treatment targets for this aggressive cancer. Patients may contribute to a global cohort that enhances our understanding of this disease.
Why it matters
Potential benefit: If successful, this research could lead to better diagnostic tools and targeted therapies for patients with EBV-positive DLBCL.
How similar studies have gone: Previous research has shown that understanding viral contributions to cancer can lead to significant advancements in treatment, suggesting potential success for this approach.
Where this research is happening
-
University of Vermont & St Agric College
Burlington, United States Active
Researchers
- Principal investigator: Volaric, Ashley Keller — University of Vermont & St Agric College
- Study coordinator: Volaric, Ashley Keller
Related research
Other NIH-funded projects on the same topics.
-
EBV-related lymphoma in people with immune deficiency: understanding what drives the disease
A doctor-scientist team will study a type of blood cancer linked to the Epstein-Barr virus in people with immune system problems to learn what makes it worse and how we can diagnose and treat it better.
-
EBV-positive diffuse large B-cell lymphoma in people with weakened immune systems
Researchers will compare tumor and virus features in people with EBV-positive diffuse large B-cell lymphoma who have weakened immune systems from HIV or medical treatments to better link biology to health outcomes.
-
Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
-
Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.